Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Empiget LT vs Glyxambi (empagliflozin + linagliptin) in healthy Thai volunteers under fasting
TCTR20260310010Phase 1Not yet recruiting
- Sponsor
- International Bio Service
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of empagliflozin + linagliptin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by International Bio Service. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
empagliflozin + linagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on TCTR20260310010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20260310010.